We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Applied Biocode, Inc.

Applied BioCode is an IVD manufacturer that designs, develops, and commercializes multiplex testing products. The com... read more Featured Products: More products

Download Mobile App

Automated Molecular Diagnostic System Transforms Lab Experience

By LabMedica International staff writers
Posted on 10 May 2023
Print article
Image: The BioCode MDx-3000 automated system maximizes sample throughput without compromising quality (Photo courtesy of Applied BioCode)
Image: The BioCode MDx-3000 automated system maximizes sample throughput without compromising quality (Photo courtesy of Applied BioCode)

Molecular diagnostics has revolutionized the treatment and management of diseases. Molecular diagnostics can detect inherited conditions, infectious diseases, and cancer, allowing medical providers to accurately diagnose conditions, discover risk factors, and guide treatment. Now, an automated molecular diagnostic system offers high sample throughput without sacrificing quality and facilitates efficient and precise testing for infectious diseases using various assays.

The BioCode MDx-3000 molecular diagnostic system from Applied BioCode, Inc. (Santa Fe Springs, CA, USA) is a user-friendly instrument based on a 96-well microplate format. It automates detection steps, PCR amplification, and hybridization and target capture. The cost-effective, high-throughput multiplex system features a simple design with a touch screen, handheld scanner, and LIS connectivity. It allows for simultaneous testing of up to three different panels in a single run and minimizes the risk of contamination.

The BioCode MDx-3000 system supports efficient and accurate testing for infectious diseases by utilizing BioCode assays, such as the Gastrointestinal Pathogen Panel, Respiratory Pathogen Panel, CoV-2 Flu Plus Assay, and SARS-CoV-2 Assay. The BioCode Gastrointestinal Pathogen Panel employs reliable Barcoded Magnetic Beads technology to detect specific gastrointestinal microbial nucleic acid from individuals exhibiting infection signs and symptoms. The flexible, cost-effective, comprehensive molecular test identifies the 17 most common causative pathogens in raw stool specimens or stool in Cary-Blair medium from symptomatic patients.

The BioCode Respiratory Pathogen Panel is a qualitative multiplexed nucleic acid-based in vitro diagnostic test that can simultaneously detect and identify nucleic acids from multiple viruses and bacteria extracted from nasopharyngeal swab (NPS) samples obtained from individuals with signs and/or symptoms of respiratory tract infection. The BioCode CoV-2 Flu Plus Assay is a multiplexed nucleic acid test designed for the qualitative detection and differentiation of RNA from SARS-CoV-2, Influenza A, Influenza B, and/or Respiratory Syncytial Virus (RSV) in nasopharyngeal swabs. It can be run as an independent assay or concurrently with the FDA-cleared BioCode Respiratory Pathogen Panel to provide a more comprehensive respiratory infection profile for patients. The BioCode SARS-CoV-2 Assay is designed to detect two different conserved regions of the SARS-CoV-2 N gene.

Related Links:
Applied BioCode, Inc. 

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Magnetic Bead Separation Modules

Print article


Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more


view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.